Table 3.
Summary of Self-Reported Cannabis Abstinence and creatinine corrected cannabinoids (ng/mg).
| Study Visit | ITT Data | Available Data | ||||
|---|---|---|---|---|---|---|
| Placebo | Varenicli ne | RR (95% CI) | Placebo | Varenicli ne | RR (95% CI) | |
| 4 | 8.1% (3) | 14.3% (5) | 1.8 (0.5,6.8) | 12.0% (3) | 22.7% (5) | 2.0 (0.5,7.3) |
| 5 | 5.4% (2) | 11.4% (4) | 2.1 (0.4,10.8) | 8.3% (2) | 17.4% (4) | 1.7 (0.4,7.2) |
| 6 | 5.4% (2) | 17.1% (6) | 3.2 (0.7,14.7) | 8.0% (2) | 27.3% (6) | 2.7 (0.7,10.0) |
| Overallƚ | 6.3% (7) | 14.3% (15) | 2.3 (0.6,8.1) | 9.5% (7) | 22.4% (15) | 2.1 (0.7,6.8) |
| Creatinine Corrected Cannabinoids (ng/mg) | Effect Size ǂ | ||||
|---|---|---|---|---|---|
| Placebo | Varenicline | Difference | Cohen’s d | Ƞ2p | |
| BL | 4.9 (2.2,7.7) | 4.8 (2.2,7.4) | 0.1 (−3.6,3.9) | -- | -- |
| 4 | 4.3 (2.0,6.7) | 2.7 (0.2,5.1) | 1.7 (−1.7,5.1) | 0.33 | -- |
| 5 | 6.2 (3.7,8.7) | 3.6 (1.2,6.0) | 2.6 (−0.9,6.1) | 0.38 | - |
| 6 | 6.7 (4.4,9.0) | 3.2 (0.7,5.6) | 3.5 (0.1,6.9)** | 0.55 | -- |
| Overallƚ | 5.8 (4.2,7.3) | 3.1 (1.6,4.7) | 2.6 (0.4,4.8)** | 0.42 | 0.026 |
Abstinence noted as self-reported abstinence from cannabis use since the last weekly visit % (n)
Creatinine corrected cannabinoid values are noted as model-based means and associated 95% Confidence intervals adjusted for baseline values.
overall treatment difference noted as the model based mean treatment effect during weeks 4–6 adjusted for baseline values.
Effect sizes are noted as Cohen’s d and are calculated using adjusted model based mean differences and pooled standard deviations. Partial eta squared values are presented for the overall main effect of treatment adjusted for baseline differences.
Notes significant within group changes from study baseline levels (p<.001).
Notes significant between group differences in changes from study baseline levels (p<.05).